img

Global and India Candida Infections Drugs Market Report & Forecast 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global and India Candida Infections Drugs Market Report & Forecast 2024-2034

Candida infection is a yeast infection where the skin acts as a host organism, and the infection multiplies and grows with the period. Candida albicans are the most common species of this infection. Candida normally lives on the skin and inside the body, such as the throat, gut, mouth, and vagina, without causing problems. It can cause infections if it grows out of control or enters deep into the body.
Market Analysis and InsightsGlobal and India Candida Infections Drugs Market
This report focuses on global and India Candida Infections Drugs market, also covers the segmentation data of other regions in regional level and county level.
The global Candida Infections Drugs revenue was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period (2024-2034).
In India the Candida Infections Drugs revenue is expected to grow from US$ million in 2024 to US$ million by 2034, at a CAGR of % during the forecast period (2024-2034).
The global key players of Candida Infections Drugs include F. Hoffmann-La Roche Ltd, Mylan NV, Teva Pharmaceutical Industries Ltd, Sanofi, Pfizer Inc, GSK plc, Novartis AG, AstraZeneca and Johnson & Johnson Private Limited, etc. The global five biggest players hold a share of % in 2024.
Global Candida Infections Drugs Scope and Market Size
Candida Infections Drugs market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global Candida Infections Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2034.
For India market, this report focuses on the Candida Infections Drugs market size by players, by Type and by Application, for the period 2018-2034. The key players include the global and local players, which play important roles in India.



By Company


F. Hoffmann-La Roche Ltd
Mylan NV
Teva Pharmaceutical Industries Ltd
Sanofi
Pfizer Inc
GSK plc
Novartis AG
AstraZeneca
Johnson & Johnson Private Limited
Sun Pharmaceutical Industries Ltd
Merck & Co., Inc
Bristol-Myers Squibb Company
Lilly
Amgen Inc
Segment by Type
Azole
Nystatin
Other

Segment by Application


Beriberi
Jock Itch
Vaginal Infection
Other
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa

Chapter Introduction


Chapter 1Introduces Candida Infections Drugs definition, global sales (volume and revenue), India market size, India percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Candida Infections Drugs companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of Candida Infections Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Candida Infections Drugs sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion

Table of Content

1 Study Coverage
1.1 Candida Infections Drugs Product Introduction
1.2 Global Candida Infections Drugs Outlook 2018 VS 2024 VS 2034
1.2.1 Global Candida Infections Drugs Sales in US$ Million for the Year 2018-2034
1.2.2 Global Candida Infections Drugs Sales in Volume for the Year 2018-2034
1.3 India Candida Infections Drugs Outlook 2018 VS 2024 VS 2034
1.3.1 India Candida Infections Drugs Sales in US$ Million for the Year 2018-2034
1.3.2 India Candida Infections Drugs Sales in Volume for the Year 2018-2034
1.4 Candida Infections Drugs Market Size, India VS Global, 2018 VS 2024 VS 2034
1.4.1 The Market Share of India Candida Infections Drugs in Global, 2018 VS 2024 VS 2034
1.4.2 The Growth Rate of Candida Infections Drugs Market Size, India VS Global, 2018 VS 2024 VS 2034
1.5 Candida Infections Drugs Market Dynamics
1.5.1 Candida Infections Drugs Industry Trends
1.5.2 Candida Infections Drugs Market Drivers
1.5.3 Candida Infections Drugs Market Challenges
1.5.4 Candida Infections Drugs Market Restraints
1.6 Study Objectives
1.7 Years Considered
1.8 Years Considered
2 Candida Infections Drugs by Type
2.1 Candida Infections Drugs Market Segment by Type
2.1.1 Azole
2.1.2 Nystatin
2.1.3 Other
2.2 Global Candida Infections Drugs Market Size by Type
2.2.1 Global Candida Infections Drugs Sales in Value, by Type (2018, 2024 & 2034)
2.2.2 Global Candida Infections Drugs Sales in Volume, by Type (2018, 2024 & 2034)
2.2.3 Global Candida Infections Drugs Average Selling Price (ASP) by Type (2018, 2024 & 2034)
2.3 India Candida Infections Drugs Market Size by Type
2.3.1 India Candida Infections Drugs Sales in Value, by Type (2018, 2024 & 2034)
2.3.2 India Candida Infections Drugs Sales in Volume, by Type (2018, 2024 & 2034)
2.3.3 India Candida Infections Drugs Average Selling Price (ASP) by Type (2018, 2024 & 2034)
3 Candida Infections Drugs by Application
3.1 Candida Infections Drugs Market Segment by Application
3.1.1 Beriberi
3.1.2 Jock Itch
3.1.3 Vaginal Infection
3.1.4 Other
3.2 Global Candida Infections Drugs Market Size by Application
3.2.1 Global Candida Infections Drugs Sales in Value, by Application (2018, 2024 & 2034)
3.2.2 Global Candida Infections Drugs Sales in Volume, by Application (2018, 2024 & 2034)
3.3.3 Global Candida Infections Drugs Average Selling Price (ASP) by Application (2018, 2024 & 2034)
3.3 India Candida Infections Drugs Market Size by Application
3.3.1 India Candida Infections Drugs Sales in Value, by Application (2018, 2024 & 2034)
3.3.2 India Candida Infections Drugs Sales in Volume, by Application (2018, 2024 & 2034)
3.3.3 India Candida Infections Drugs Average Selling Price (ASP) by Application (2018, 2024 & 2034)
4 Global Candida Infections Drugs Competitor Landscape by Company
4.1 Global Candida Infections Drugs Market Size by Company
4.1.1 Global Key Manufacturers of Candida Infections Drugs, Ranked by Revenue (2024)
4.1.2 Global Candida Infections Drugs Revenue by Manufacturer (2018-2023)
4.1.3 Global Candida Infections Drugs Sales by Manufacturer (2018-2023)
4.1.4 Global Candida Infections Drugs Price by Manufacturer (2018-2023)
4.2 Global Candida Infections Drugs Concentration Ratio (CR)
4.2.1 Candida Infections Drugs Market Concentration Ratio (CR)
4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Candida Infections Drugs in 2024
4.2.3 Global Candida Infections Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Key Manufacturers of Candida Infections Drugs, Manufacturing Base Distribution and Headquarters
4.4 Global Key Manufacturers of Candida Infections Drugs, Product Offered and Application
4.5 Global Key Manufacturers of Candida Infections Drugs, Date of Enter into This Industry
4.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4.7 India Candida Infections Drugs Market Size by Company
4.7.1 Key Players of Candida Infections Drugs in India, Ranked by Revenue (2024)
4.7.2 India Candida Infections Drugs Revenue by Players (2018-2023)
4.7.3 India Candida Infections Drugs Sales by Players (2018-2023)
5 Global Candida Infections Drugs Market Size by Region
5.1 Global Candida Infections Drugs Market Size by Region: 2018 VS 2024 VS 2034
5.2 Global Candida Infections Drugs Market Size in Volume by Region (2018-2034)
5.2.1 Global Candida Infections Drugs Sales in Volume by Region: 2018-2023
5.2.2 Global Candida Infections Drugs Sales in Volume Forecast by Region (2024-2034)
5.3 Global Candida Infections Drugs Market Size in Value by Region (2018-2034)
5.3.1 Global Candida Infections Drugs Sales in Value by Region: 2018-2023
5.3.2 Global Candida Infections Drugs Sales in Value by Region: 2024-2034
6 Americas
6.1 Americas Candida Infections Drugs Market Size YoY Growth 2018-2034
6.2 Americas Candida Infections Drugs Sales in Volume, by Type (2018, 2024 & 2034)
6.3 Americas Candida Infections Drugs Sales in Volume, by Application (2018, 2024 & 2034)
6.4 Americas Candida Infections Drugs Market Facts & Figures by Country (2018, 2024 & 2034)
6.4.1 Americas Candida Infections Drugs Sales in Value by Country (2018, 2024 & 2034)
6.4.2 Americas Candida Infections Drugs Sales in Volume by Country (2018, 2024 & 2034)
6.4.3 United States
6.4.4 Canada
6.4.5 Mexico
6.4.6 Brazil
7 EMEA
7.1 EMEA Candida Infections Drugs Market Size YoY Growth 2018-2034
7.2 EMEA Candida Infections Drugs Sales in Volume, by Type (2018, 2024 & 2034)
7.3 EMEA Candida Infections Drugs Sales in Volume, by Application (2018, 2024 & 2034)
7.4 EMEA Candida Infections Drugs Market Facts & Figures by Country (2018, 2024 & 2034)
7.4.1 EMEA Candida Infections Drugs Sales in Value by Country (2018, 2024 & 2034)
7.4.2 EMEA Candida Infections Drugs Sales in Volume by Country (2018, 2024 & 2034)
7.4.3 Europe
7.4.4 Middle East
7.4.5 Africa
8 China
8.1 China Candida Infections Drugs Market Size YoY Growth 2018-2034
8.2 China Candida Infections Drugs Sales in Volume, by Type (2018, 2024 & 2034)
8.3 China Candida Infections Drugs Sales in Volume, by Application (2018, 2024 & 2034)
9 APAC
9.1 APAC Candida Infections Drugs Market Size YoY Growth 2018-2034
9.2 APAC Candida Infections Drugs Sales in Volume, by Type (2018, 2024 & 2034)
9.3 APAC Candida Infections Drugs Sales in Volume, by Application (2018, 2024 & 2034)
9.4 APAC Candida Infections Drugs Market Facts & Figures by Region (2018, 2024 & 2034)
9.4.1 APAC Candida Infections Drugs Sales in Value by Region (2018, 2024 & 2034)
9.4.2 APAC Candida Infections Drugs Sales in Volume by Region (2018, 2024 & 2034)
9.4.3 Japan
9.4.4 South Korea
9.4.5 China Taiwan
9.4.6 Southeast Asia
9.4.7 India
10 Company Profiles
10.1 F. Hoffmann-La Roche Ltd
10.1.1 F. Hoffmann-La Roche Ltd Company Information
10.1.2 F. Hoffmann-La Roche Ltd Description and Business Overview
10.1.3 F. Hoffmann-La Roche Ltd Candida Infections Drugs Sales, Revenue and Gross Margin (2018-2023)
10.1.4 F. Hoffmann-La Roche Ltd Candida Infections Drugs Products Offered
10.1.5 F. Hoffmann-La Roche Ltd Recent Development
10.2 Mylan NV
10.2.1 Mylan NV Company Information
10.2.2 Mylan NV Description and Business Overview
10.2.3 Mylan NV Candida Infections Drugs Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Mylan NV Candida Infections Drugs Products Offered
10.2.5 Mylan NV Recent Development
10.3 Teva Pharmaceutical Industries Ltd
10.3.1 Teva Pharmaceutical Industries Ltd Company Information
10.3.2 Teva Pharmaceutical Industries Ltd Description and Business Overview
10.3.3 Teva Pharmaceutical Industries Ltd Candida Infections Drugs Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Teva Pharmaceutical Industries Ltd Candida Infections Drugs Products Offered
10.3.5 Teva Pharmaceutical Industries Ltd Recent Development
10.4 Sanofi
10.4.1 Sanofi Company Information
10.4.2 Sanofi Description and Business Overview
10.4.3 Sanofi Candida Infections Drugs Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Sanofi Candida Infections Drugs Products Offered
10.4.5 Sanofi Recent Development
10.5 Pfizer Inc
10.5.1 Pfizer Inc Company Information
10.5.2 Pfizer Inc Description and Business Overview
10.5.3 Pfizer Inc Candida Infections Drugs Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Pfizer Inc Candida Infections Drugs Products Offered
10.5.5 Pfizer Inc Recent Development
10.6 GSK plc
10.6.1 GSK plc Company Information
10.6.2 GSK plc Description and Business Overview
10.6.3 GSK plc Candida Infections Drugs Sales, Revenue and Gross Margin (2018-2023)
10.6.4 GSK plc Candida Infections Drugs Products Offered
10.6.5 GSK plc Recent Development
10.7 Novartis AG
10.7.1 Novartis AG Company Information
10.7.2 Novartis AG Description and Business Overview
10.7.3 Novartis AG Candida Infections Drugs Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Novartis AG Candida Infections Drugs Products Offered
10.7.5 Novartis AG Recent Development
10.8 AstraZeneca
10.8.1 AstraZeneca Company Information
10.8.2 AstraZeneca Description and Business Overview
10.8.3 AstraZeneca Candida Infections Drugs Sales, Revenue and Gross Margin (2018-2023)
10.8.4 AstraZeneca Candida Infections Drugs Products Offered
10.8.5 AstraZeneca Recent Development
10.9 Johnson & Johnson Private Limited
10.9.1 Johnson & Johnson Private Limited Company Information
10.9.2 Johnson & Johnson Private Limited Description and Business Overview
10.9.3 Johnson & Johnson Private Limited Candida Infections Drugs Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Johnson & Johnson Private Limited Candida Infections Drugs Products Offered
10.9.5 Johnson & Johnson Private Limited Recent Development
10.10 Sun Pharmaceutical Industries Ltd
10.10.1 Sun Pharmaceutical Industries Ltd Company Information
10.10.2 Sun Pharmaceutical Industries Ltd Description and Business Overview
10.10.3 Sun Pharmaceutical Industries Ltd Candida Infections Drugs Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Sun Pharmaceutical Industries Ltd Candida Infections Drugs Products Offered
10.10.5 Sun Pharmaceutical Industries Ltd Recent Development
10.11 Merck & Co., Inc
10.11.1 Merck & Co., Inc Company Information
10.11.2 Merck & Co., Inc Description and Business Overview
10.11.3 Merck & Co., Inc Candida Infections Drugs Sales, Revenue and Gross Margin (2018-2023)
10.11.4 Merck & Co., Inc Candida Infections Drugs Products Offered
10.11.5 Merck & Co., Inc Recent Development
10.12 Bristol-Myers Squibb Company
10.12.1 Bristol-Myers Squibb Company Company Information
10.12.2 Bristol-Myers Squibb Company Description and Business Overview
10.12.3 Bristol-Myers Squibb Company Candida Infections Drugs Sales, Revenue and Gross Margin (2018-2023)
10.12.4 Bristol-Myers Squibb Company Candida Infections Drugs Products Offered
10.12.5 Bristol-Myers Squibb Company Recent Development
10.13 Lilly
10.13.1 Lilly Company Information
10.13.2 Lilly Description and Business Overview
10.13.3 Lilly Candida Infections Drugs Sales, Revenue and Gross Margin (2018-2023)
10.13.4 Lilly Candida Infections Drugs Products Offered
10.13.5 Lilly Recent Development
10.14 Amgen Inc
10.14.1 Amgen Inc Company Information
10.14.2 Amgen Inc Description and Business Overview
10.14.3 Amgen Inc Candida Infections Drugs Sales, Revenue and Gross Margin (2018-2023)
10.14.4 Amgen Inc Candida Infections Drugs Products Offered
10.14.5 Amgen Inc Recent Development
11 Industry Chain and Sales Channels Analysis
11.1 Candida Infections Drugs Industry Chain Analysis
11.2 Candida Infections Drugs Key Raw Materials
11.2.1 Key Raw Materials
11.2.2 Raw Materials Key Suppliers
11.3 Candida Infections Drugs Production Mode & Process
11.4 Candida Infections Drugs Sales and Marketing
11.4.1 Candida Infections Drugs Sales Channels
11.4.2 Candida Infections Drugs Distributors
11.5 Candida Infections Drugs Customers
12 Research Findings and Conclusion
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

List of Figure

List of Tables
Table 1. Candida Infections Drugs CAGR in Value, India VS Global, 2018 VS 2024 VS 2034
Table 2. Candida Infections Drugs Market Trends
Table 3. Candida Infections Drugs Market Drivers
Table 4. Candida Infections Drugs Market Challenges
Table 5. Candida Infections Drugs Market Restraints
Table 6. Global Candida Infections Drugs Sales Growth Rate (CAGR) by Type: 2018 VS 2024 VS 2034 (US$ Million)
Table 7. India Candida Infections Drugs Sales Growth Rate (CAGR) by Type: 2018 VS 2024 VS 2034 (US$ Million)
Table 8. Global Candida Infections Drugs Sales Growth Rate (CAGR) by Application: 2018 VS 2024 VS 2034 (US$ Million)
Table 9. India Candida Infections Drugs Sales Growth Rate (CAGR) by Application: 2018 VS 2024 VS 2034 (US$ Million)
Table 10. Global Key Manufacturers of Candida Infections Drugs, Ranked by Revenue (2024) & (US$ Million)
Table 11. Global Candida Infections Drugs Revenue by Manufacturer, (US$ Million), 2018-2023
Table 12. Global Candida Infections Drugs Revenue Share by Manufacturer, 2018-2023
Table 13. Global Candida Infections Drugs Sales by Manufacturer, (K Units), 2018-2023
Table 14. Global Candida Infections Drugs Sales Share by Manufacturer, 2018-2023
Table 15. Global Candida Infections Drugs Price by Manufacturer (2018-2023) & (US$/Unit)
Table 16. Global Candida Infections Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global Candida Infections Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Candida Infections Drugs as of 2024)
Table 18. Global Key Manufacturers of Candida Infections Drugs, Manufacturing Base Distribution and Headquarters
Table 19. Global Key Manufacturers of Candida Infections Drugs, Product Offered and Application
Table 20. Global Key Manufacturers of Candida Infections Drugs, Date of Enter into This Industry
Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 22. Key Players of Candida Infections Drugs in India, Ranked by Revenue (2024) & (US$ million)
Table 23. India Candida Infections Drugs Revenue by Players, (US$ Million), (2018-2023)
Table 24. India Candida Infections Drugs Revenue Share by Players, (2018-2023)
Table 25. India Candida Infections Drugs Sales by Players, (K Units), (2018-2023)
Table 26. India Candida Infections Drugs Sales Share by Players, (2018-2023)
Table 27. Global Candida Infections Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2024 VS 2034
Table 28. Global Candida Infections Drugs Sales in Volume by Region (2018-2023) & (K Units)
Table 29. Global Candida Infections Drugs Sales in Volume Forecast by Region (2024-2034) & (K Units)
Table 30. Global Candida Infections Drugs Sales in Value by Region (2018-2023) & (US$ Million)
Table 31. Global Candida Infections Drugs Sales in Value Forecast by Region (2024-2034) & (US$ Million)
Table 32. Americas Candida Infections Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 33. Americas Candida Infections Drugs Sales in Value by Country (2018-2023) & (US$ Million)
Table 34. Americas Candida Infections Drugs Sales in Value by Country (2024-2034) & (US$ Million)
Table 35. Americas Candida Infections Drugs Sales in Volume by Country (2018-2023) & (K Units)
Table 36. Americas Candida Infections Drugs Sales in Volume by Country (2024-2034) & (K Units)
Table 37. EMEA Candida Infections Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 38. EMEA Candida Infections Drugs Sales in Value by Country (2018-2023) & (US$ Million)
Table 39. EMEA Candida Infections Drugs Sales in Value by Country (2024-2034) & (US$ Million)
Table 40. EMEA Candida Infections Drugs Sales in Volume by Country (2018-2023) & (K Units)
Table 41. EMEA Candida Infections Drugs Sales in Volume by Country (2024-2034) & (K Units)
Table 42. APAC Candida Infections Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2024 VS 2034
Table 43. APAC Candida Infections Drugs Sales in Value by Country (2018-2023) & (US$ Million)
Table 44. APAC Candida Infections Drugs Sales in Value by Country (2024-2034) & (US$ Million)
Table 45. APAC Candida Infections Drugs Sales in Volume by Country (2018-2023) & (K Units)
Table 46. APAC Candida Infections Drugs Sales in Volume by Country (2024-2034) & (K Units)
Table 47. F. Hoffmann-La Roche Ltd Company Information
Table 48. F. Hoffmann-La Roche Ltd Description and Business Overview
Table 49. F. Hoffmann-La Roche Ltd Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 50. F. Hoffmann-La Roche Ltd Candida Infections Drugs Product
Table 51. F. Hoffmann-La Roche Ltd Recent Development
Table 52. Mylan NV Company Information
Table 53. Mylan NV Description and Business Overview
Table 54. Mylan NV Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 55. Mylan NV Candida Infections Drugs Product
Table 56. Mylan NV Recent Development
Table 57. Teva Pharmaceutical Industries Ltd Company Information
Table 58. Teva Pharmaceutical Industries Ltd Description and Business Overview
Table 59. Teva Pharmaceutical Industries Ltd Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 60. Teva Pharmaceutical Industries Ltd Candida Infections Drugs Product
Table 61. Teva Pharmaceutical Industries Ltd Recent Development
Table 62. Sanofi Company Information
Table 63. Sanofi Description and Business Overview
Table 64. Sanofi Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 65. Sanofi Candida Infections Drugs Product
Table 66. Sanofi Recent Development
Table 67. Pfizer Inc Company Information
Table 68. Pfizer Inc Description and Business Overview
Table 69. Pfizer Inc Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 70. Pfizer Inc Candida Infections Drugs Product
Table 71. Pfizer Inc Recent Development
Table 72. GSK plc Company Information
Table 73. GSK plc Description and Business Overview
Table 74. GSK plc Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 75. GSK plc Candida Infections Drugs Product
Table 76. GSK plc Recent Development
Table 77. Novartis AG Company Information
Table 78. Novartis AG Description and Business Overview
Table 79. Novartis AG Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 80. Novartis AG Candida Infections Drugs Product
Table 81. Novartis AG Recent Development
Table 82. AstraZeneca Company Information
Table 83. AstraZeneca Description and Business Overview
Table 84. AstraZeneca Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 85. AstraZeneca Candida Infections Drugs Product
Table 86. AstraZeneca Recent Development
Table 87. Johnson & Johnson Private Limited Company Information
Table 88. Johnson & Johnson Private Limited Description and Business Overview
Table 89. Johnson & Johnson Private Limited Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 90. Johnson & Johnson Private Limited Candida Infections Drugs Product
Table 91. Johnson & Johnson Private Limited Recent Development
Table 92. Sun Pharmaceutical Industries Ltd Company Information
Table 93. Sun Pharmaceutical Industries Ltd Description and Business Overview
Table 94. Sun Pharmaceutical Industries Ltd Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 95. Sun Pharmaceutical Industries Ltd Candida Infections Drugs Product
Table 96. Sun Pharmaceutical Industries Ltd Recent Development
Table 97. Merck & Co., Inc Company Information
Table 98. Merck & Co., Inc Description and Business Overview
Table 99. Merck & Co., Inc Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 100. Merck & Co., Inc Candida Infections Drugs Product
Table 101. Merck & Co., Inc Recent Development
Table 102. Bristol-Myers Squibb Company Company Information
Table 103. Bristol-Myers Squibb Company Description and Business Overview
Table 104. Bristol-Myers Squibb Company Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 105. Bristol-Myers Squibb Company Candida Infections Drugs Product
Table 106. Bristol-Myers Squibb Company Recent Development
Table 107. Lilly Company Information
Table 108. Lilly Description and Business Overview
Table 109. Lilly Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 110. Lilly Candida Infections Drugs Product
Table 111. Lilly Recent Development
Table 112. Amgen Inc Company Information
Table 113. Amgen Inc Description and Business Overview
Table 114. Amgen Inc Candida Infections Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 115. Amgen Inc Candida Infections Drugs Product
Table 116. Amgen Inc Recent Development
Table 117. Key Raw Materials Lists
Table 118. Raw Materials Key Suppliers Lists
Table 119. Candida Infections Drugs Customers List
Table 120. Candida Infections Drugs Distributors List
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources
List of Figures
Figure 1. Candida Infections Drugs Product Picture
Figure 2. Global Candida Infections Drugs Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 3. Global Candida Infections Drugs Market Size 2018-2034 (US$ Million)
Figure 4. Global Candida Infections Drugs Sales 2018-2034 (K Units)
Figure 5. India Candida Infections Drugs Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 6. India Candida Infections Drugs Market Size 2018-2034 (US$ Million)
Figure 7. India Candida Infections Drugs Sales 2018-2034 (K Units)
Figure 8. India Candida Infections Drugs Market Share in Global, in Value (US$ Million) 2018-2034
Figure 9. India Candida Infections Drugs Market Share in Global, in Volume (K Units) 2018-2034
Figure 10. Candida Infections Drugs Report Years Considered
Figure 11. Product Picture of Azole
Figure 12. Product Picture of Nystatin
Figure 13. Product Picture of Other
Figure 14. Global Candida Infections Drugs Market Share by Type in 2024 & 2034
Figure 15. Global Candida Infections Drugs Sales in Value by Type (2018-2034) & (US$ Million)
Figure 16. Global Candida Infections Drugs Sales Market Share in Value by Type (2018-2034)
Figure 17. Global Candida Infections Drugs Sales by Type (2018-2034) & (K Units)
Figure 18. Global Candida Infections Drugs Sales Market Share in Volume by Type (2018-2034)
Figure 19. Global Candida Infections Drugs Price by Type (2018-2034) & (US$/Unit)
Figure 20. India Candida Infections Drugs Market Share by Type in 2024 & 2034
Figure 21. India Candida Infections Drugs Sales in Value by Type (2018-2034) & (US$ Million)
Figure 22. India Candida Infections Drugs Sales Market Share in Value by Type (2018-2034)
Figure 23. India Candida Infections Drugs Sales by Type (2018-2034) & (K Units)
Figure 24. India Candida Infections Drugs Sales Market Share in Volume by Type (2018-2034)
Figure 25. India Candida Infections Drugs Price by Type (2018-2034) & (US$/Unit)
Figure 26. Product Picture of Beriberi
Figure 27. Product Picture of Jock Itch
Figure 28. Product Picture of Vaginal Infection
Figure 29. Product Picture of Other
Figure 30. Global Candida Infections Drugs Market Share by Application in 2024 & 2034
Figure 31. Global Candida Infections Drugs Sales in Value by Application (2018-2034) & (US$ Million)
Figure 32. Global Candida Infections Drugs Sales Market Share in Value by Application (2018-2034)
Figure 33. Global Candida Infections Drugs Sales by Application (2018-2034) & (K Units)
Figure 34. Global Candida Infections Drugs Sales Market Share in Volume by Application (2018-2034)
Figure 35. Global Candida Infections Drugs Price by Application (2018-2034) & (US$/Unit)
Figure 36. India Candida Infections Drugs Market Share by Application in 2024 & 2034
Figure 37. India Candida Infections Drugs Sales in Value by Application (2018-2034) & (US$ Million)
Figure 38. India Candida Infections Drugs Sales Market Share in Value by Application (2018-2034)
Figure 39. India Candida Infections Drugs Sales by Application (2018-2034) & (K Units)
Figure 40. India Candida Infections Drugs Sales Market Share in Volume by Application (2018-2034)
Figure 41. India Candida Infections Drugs Price by Application (2018-2034) & (US$/Unit)
Figure 42. Americas Candida Infections Drugs Sales in Volume Growth Rate 2018-2034 (K Units)
Figure 43. Americas Candida Infections Drugs Sales in Value Growth Rate 2018-2034 (US$ Million)
Figure 44. Americas Candida Infections Drugs Sales by Type (2018-2034) & (K Units)
Figure 45. Americas Candida Infections Drugs Sales Market Share in Volume by Type (2018-2034)
Figure 46. Americas Candida Infections Drugs Sales by Application (2018-2034) & (K Units)
Figure 47. Americas Candida Infections Drugs Sales Market Share in Volume by Application (2018-2034)
Figure 48. United States Candida Infections Drugs Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 49. Canada Candida Infections Drugs Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 50. Mexico Candida Infections Drugs Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 51. Brazil Candida Infections Drugs Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 52. EMEA Candida Infections Drugs Sales in Volume Growth Rate 2018-2034 (K Units)
Figure 53. EMEA Candida Infections Drugs Sales in Value Growth Rate 2018-2034 (US$ Million)
Figure 54. EMEA Candida Infections Drugs Sales by Type (2018-2034) & (K Units)
Figure 55. EMEA Candida Infections Drugs Sales Market Share in Volume by Type (2018-2034)
Figure 56. EMEA Candida Infections Drugs Sales by Application (2018-2034) & (K Units)
Figure 57. EMEA Candida Infections Drugs Sales Market Share in Volume by Application (2018-2034)
Figure 58. Europe Candida Infections Drugs Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 59. Middle East Candida Infections Drugs Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 60. Africa Candida Infections Drugs Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 61. China Candida Infections Drugs Sales in Volume Growth Rate 2018-2034 (K Units)
Figure 62. China Candida Infections Drugs Sales in Value Growth Rate 2018-2034 (US$ Million)
Figure 63. China Candida Infections Drugs Sales by Type (2018-2034) & (K Units)
Figure 64. China Candida Infections Drugs Sales Market Share in Volume by Type (2018-2034)
Figure 65. China Candida Infections Drugs Sales by Application (2018-2034) & (K Units)
Figure 66. China Candida Infections Drugs Sales Market Share in Volume by Application (2018-2034)
Figure 67. APAC Candida Infections Drugs Sales in Volume Growth Rate 2018-2034 (K Units)
Figure 68. APAC Candida Infections Drugs Sales in Value Growth Rate 2018-2034 (US$ Million)
Figure 69. APAC Candida Infections Drugs Sales by Type (2018-2034) & (K Units)
Figure 70. APAC Candida Infections Drugs Sales Market Share in Volume by Type (2018-2034)
Figure 71. APAC Candida Infections Drugs Sales by Application (2018-2034) & (K Units)
Figure 72. APAC Candida Infections Drugs Sales Market Share in Volume by Application (2018-2034)
Figure 73. Japan Candida Infections Drugs Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 74. South Korea Candida Infections Drugs Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 75. China Taiwan Candida Infections Drugs Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 76. Southeast Asia Candida Infections Drugs Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 77. India Candida Infections Drugs Sales in Value Growth Rate (2018-2034) & (US$ Million)
Figure 78. Candida Infections Drugs Value Chain
Figure 79. Candida Infections Drugs Production Process
Figure 80. Channels of Distribution
Figure 81. Distributors Profiles
Figure 82. Bottom-up and Top-down Approaches for This Report
Figure 83. Data Triangulation
Figure 84. Key Executives Interviewed